Non-small-cell lung cancer with an EGFR exon 20 insertion mutation is a subtype of lung cancer marked by a rare genetic change in the gene that codes for a protein on the surface of cells called EGFR. In exon 20 insertion mutations, extra genetic material gets added to the genetic code that makes cancer cells grow out of control.
This mutation tells doctors a lot about how your cancer may – or may not – respond to certain lung cancer treatments. EGFR exon 20 insertion-mutated cancer doesn’t typically respond well to older targeted therapies for EGFR-positive lung cancer. That has made treating it especially hard.
Most EGFR-targeted therapies work by sliding into a specific spot called a binding pocket on the abnormal protein. When they fit in this pocket, they block the “grow” signal that the mutation is creating.
But because exon 20 insertions add more to the pocket, it changes the pocket’s shape. That structural difference is why standard drugs for other EGFR mutations (like exon 19 deletions or exon 21 L858R) don’t work as well for exon 20 insertions. Older drugs simply don’t “fit” well enough to be effective.
“I always explain it to my patients like this: This mutation is the ‘on switch’ for your cancer cells to keep growing,” says Angel Qin, MD, a medical oncologist at the University of Michigan. “The idea behind all of our treatments is to try to find an ‘off switch.’ Essentially, it's like looking for a missing puzzle piece that can stop the whole process.”
The goal of current research in EGFR exon 20 insertion treatment is focused on finding that missing piece.
The Most Recent Advancements in Treatment
Research has come a long way in the past several years, leading to new FDA-approved drugs for EGFR exon 20 insertion mutations.
Amivantamab (Rybrevant)
In March 2024, the FDA approved amivantamab (Rybrevant), a type of targeted therapy called a bispecific antibody, as a first-line treatment (in combination with platinum-doublet chemotherapy) for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. Doctors can also prescribe it solo for people whose cancer has stopped responding after chemotherapy. In December 2025, the FDA approved Rybrevant Faspro as the first subcutaneous EGFR-targeted therapy for EGFR-mutated NSCLC. In February 2026, the FDA approved an every-four-weeks dosing schedule of Rybrevant Faspro.
Instead of trying to fit into the mutated binding pocket, amivantamab sticks to the outside of the cancer cell in two places – EGFR and another growth-related protein called MET.
In clinical trials, people who took this amivantamab/chemo combination lived longer without their cancer getting worse compared to those who had chemotherapy alone.
Sunvozertinib (Zegfrovy)
Another breakthrough came in July 2025, when the FDA granted accelerated approval to sunvozertinib (Zegfrovy) for adults with metastatic or advanced NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy.
“Sunvozertinib is what we consider a tyrosine kinase inhibitor,” says Qin. “It’s a drug that fits into that pocket better.”
Sunvozertinib is a targeted oral therapy that blocks the abnormal EGFR protein directly. You take it as a pill once a day. In the clinical trial that helped it gain approval, about 46% of people had their tumors shrink, and this benefit lasted about 11 months on average.
The FDA also approved a companion test (Oncomine Dx Express Test) that helps doctors identify people whose tumors have the exon 20 insertion, so they know who might benefit from sunvozertinib.
Qin says another positive thing about sunvozertinib is that its side effects aren’t as severe as those of previous exon 20 mutation-specific treatments.
“When we make a drug, we have to make sure not only that it's specific for the mutation, but that it's not causing too much toxicity to the rest of the normal body,” she says. “Previous drugs that were developed for EGFR exon 20 had to be withdrawn from the market because they were just too toxic.”
Ongoing and Future Clinical Research
Research continues so that doctors can offer more effective treatments that last longer. Two more tyrosine kinase inhibitors are in clinical trials.
Zipalertinib
Early data on this tyrosine kinase inhibitor has shown promising results. Around 40% of people who take it have a positive response. Even for people who have already taken amivantamab, the response rate was about 50%. The disease control rate (meaning tumors didn’t grow) was about 90%, and the average span of time people saw no progression was nearly 10 months.
This means zipalertinib could be another option for people who have already taken other therapies, but research is still ongoing.
Furmonertinib and other experimental therapies
Another promising tyrosine kinase inhibitor is furmonertinib, which has encouraging results in early studies. In the first phases of clinical trials, some data shows the drug works in over 60% of people.
Researchers are also actively studying how certain drugs can be combined and new drug classes that can help overcome treatment resistance and help people have longer remissions.
“Once we see more data come out from these drug trials and approvals start to happen, the biggest question becomes how to best sequence them, combine them, or potentially find a role for them as first-line treatments or even in earlier-stage disease,” Qin says.
The Importance of Molecular Testing
Advancements in treatment for EGFR exon 20 insertion-mutated cancer is only helpful when doctors know who to use those treatments on. Qin says comprehensive molecular testing (examining the tumor DNA for specific changes) at the time of your diagnosis is critical.
“We can't offer any of our treatments unless we know that an actionable mutation is present,” says Qin. “I strongly advise talking to your oncologist about whether molecular profiling is appropriate for you. And if it is, get a copy of your report.“
Not only does this empower you to make more informed decisions about your treatment, it tells your team what treatments will work best on you – and helps improve data on who lives with this cancer subtype so more advancements can be made.
